新型调脂药培马贝特在治疗应用中的研究进展

Research progress of a new lipid-regulating drug pemafibrate in therapeutic application

培马贝特为日本研制开发的新型贝特类药物,于2018年6月在日本批准上市。相比于传统的贝特类药物,培马贝特可以更具目标性地与过氧化物酶体增殖物激活受体α(PPARα)结合,进而高效地发挥调脂作用。研究表明,培马贝特在改善血脂水平的同时,还可以调节血糖、维持肝脏代谢、抑制炎症和血栓形成,在患有糖尿病、肝脏病变及心血管疾病的人群中可能具有一定应用价值,其常见的不良反应为过敏、鼻咽炎、肌酸激酶升高和血尿酸升高等。

Pemafibrate,a new type of fibrates developed in Japan,was approved for marketing in Japan in June 2018.Compared with traditional fibrates,pemafibrate can combine peroxisome proliferator activated receptorα(PPARa)purposefully,and then regulate lipid metabolism effectively.Studies have shown that pemafibrate can not only improve blood lipid levels,but also regulate blood glucose,maintain liver metabolism,inhibit inflammation and thrombosis,and may have certain application value in people with diabetes,liver diseases,and cardiovascular diseases.The common adverse reactions are allergy,nasopharyngitis,creatine kinase elevation,blood uric acid elevation and so on.